Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Pembrolizumab in Cancer of Unknown Primary (CUPem)

NCT03752333 is registered in ClinicalTrials.gov with Imperial College London as lead sponsor.

NCT NCT03752333
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03752333 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Pembrolizumab in Cancer of Unknown Primary (CUPem)
Lead sponsor
Imperial College London
Phase
Phase 2
Overall status
Completed
Start date
February 22, 2019
Completion date
March 31, 2025
Enrollment
35 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of unknown primary site